Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/02/2022* -- Results Q1 2023 -- 0.61 --
11/02/2022* 08:15 EST Earnings Call Q1 2023 -- -- --
08/29/2022 -- Results Q4 2022 1.19 1.15 3.68%
08/29/2022 08:15 EST Earnings Call Q4 2022 -- -- --
05/03/2022 -- Results Q3 2022 1.04 0.94 10.62%
05/03/2022 08:15 EST Earnings Call Q3 2022 -- -- --
02/01/2022 -- Results Q2 2022 0.90 0.83 7.85%
02/01/2022 08:15 EST Earnings Call Q2 2022 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/02/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/29/2022
Beat/Miss Upgrade
Return Since -21.59%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
URL https://www.catalent.com
Investor Relations URL https://investor.catalent.com
HQ State/Province New Jersey
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Equity Style Mid Cap/Growth
Next Earnings Release Nov. 02, 2022 (est.)
Last Earnings Release Aug. 29, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.77%
Cash Payout Ratio -1.81%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-10.22%
7.71%
52.37%
-24.10%
80.56%
84.85%
23.02%
-43.48%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-23.87%
--
--
--
--
--
136.2%
71.93%
55.93%
--
--
--
--
28.09%
434.1%
143.1%
-53.44%
-77.77%
-48.60%
0.65%
-44.49%
-21.01%
137.9%
33.13%
-69.98%
--
--
--
--
-16.34%
-43.76%
101.3%
-30.87%
As of September 30, 2022.

Profile

Edit
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
URL https://www.catalent.com
Investor Relations URL https://investor.catalent.com
HQ State/Province New Jersey
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Equity Style Mid Cap/Growth
Next Earnings Release Nov. 02, 2022 (est.)
Last Earnings Release Aug. 29, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
MJJ 2.345M USD 4.79%
APDMX 204.94M USD 4.52%
IHE 14.94M USD 3.85%
JGMCX 229.74M USD 3.10%
PPH 16.60M USD 2.97%
XPH 6.081M USD 2.87%
PMEGX 135.19M USD 2.79%
FVUSA04AZ9 133.79M USD 2.71%
RRMGX 740.30M USD 2.70%
GRX 5.901M USD 2.03%
ZUH.TO 6.977M USD 1.66%
JDMRX 243.03M USD 1.43%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter CTLT Tweets